Literature DB >> 23802701

Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease.

Olufolake A Adisa1, Yijuan Hu, Samit Ghosh, Doreen Aryee, Ifeyinwa Osunkwo, Solomon F Ofori-Acquah.   

Abstract

We tested the hypothesis that extracellular haem is linked to the incidence of acute complications of sickle cell disease (SCD). Using multivariable regression analysis, higher plasma free haem, but not total plasma haem, was associated with increased odds of vaso-occlusive crisis (VOC) [P = 0·028, odds ratio (OR); 2·05, 95% Confidence Interval (CI) = 1·08-3·89] and acute chest syndrome (ACS) [P = 0·016, OR; 2·56, CI = 1·19, 5·47], after adjusting for age and gender in children with SCD. These findings suggest that haem and factors that influence its concentration in plasma may be informative of the risk of VOC and ACS in SCD patients.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  acute chest syndrome; extracellular haem; sickle cell disease; vaso-occlusive pain crisis

Mesh:

Substances:

Year:  2013        PMID: 23802701      PMCID: PMC3745813          DOI: 10.1111/bjh.12445

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Exchange of heme among hemoglobins and between hemoglobin and albumin.

Authors:  H F Bunn; J H Jandl
Journal:  J Biol Chem       Date:  1968-02-10       Impact factor: 5.157

2.  Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases.

Authors:  U Muller-Eberhard; J Javid; H H Liem; A Hanstein; M Hanna
Journal:  Blood       Date:  1968-11       Impact factor: 22.113

3.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

4.  Pain in sickle cell disease. Rates and risk factors.

Authors:  O S Platt; B D Thorington; D J Brambilla; P F Milner; W F Rosse; E Vichinsky; T R Kinney
Journal:  N Engl J Med       Date:  1991-07-04       Impact factor: 91.245

5.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Authors:  T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

6.  Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria.

Authors:  Ana Pamplona; Ana Ferreira; József Balla; Viktória Jeney; György Balla; Sabrina Epiphanio; Angelo Chora; Cristina D Rodrigues; Isabel Pombo Gregoire; Margarida Cunha-Rodrigues; Silvia Portugal; Miguel P Soares; Maria M Mota
Journal:  Nat Med       Date:  2007-05-13       Impact factor: 53.440

7.  Pro-oxidant and cytotoxic effects of circulating heme.

Authors:  Viktória Jeney; József Balla; Akihiro Yachie; Zsuzsa Varga; Gregory M Vercellotti; John W Eaton; György Balla
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Heme oxygenase-1 affords protection against noncerebral forms of severe malaria.

Authors:  Elsa Seixas; Raffaella Gozzelino; Angelo Chora; Ana Ferreira; Gabriela Silva; Rasmus Larsen; Sofia Rebelo; Carmen Penido; Neal R Smith; Antonio Coutinho; Miguel P Soares
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

9.  The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe.

Authors:  Mehdi Nouraie; Janet S Lee; Yingze Zhang; Tamir Kanias; Xuejun Zhao; Zeyu Xiong; Timothy B Oriss; Qilu Zeng; Gregory J Kato; J Simon R Gibbs; Mariana E Hildesheim; Vandana Sachdev; Robyn J Barst; Roberto F Machado; Kathryn L Hassell; Jane A Little; Dean E Schraufnagel; Lakshmanan Krishnamurti; Enrico Novelli; Reda E Girgis; Claudia R Morris; Erika Berman Rosenzweig; David B Badesch; Sophie Lanzkron; Oswaldo L Castro; Jonathan C Goldsmith; Victor R Gordeuk; Mark T Gladwin
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

10.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

View more
  26 in total

Review 1.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

2.  Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice.

Authors:  Samit Ghosh; Chibueze A Ihunnah; Rimi Hazra; Aisha L Walker; Jason M Hansen; David R Archer; Amma T Owusu-Ansah; Solomon F Ofori-Acquah
Journal:  JCI Insight       Date:  2016-04-07

Review 3.  The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia.

Authors:  Michael R DeBaun; Robert C Strunk
Journal:  Lancet       Date:  2016-06-18       Impact factor: 79.321

4.  The free heme concentration in healthy human erythrocytes.

Authors:  Anupam Aich; Melissa Freundlich; Peter G Vekilov
Journal:  Blood Cells Mol Dis       Date:  2015-09-21       Impact factor: 3.039

5.  Free heme regulates placenta growth factor through NRF2-antioxidant response signaling.

Authors:  Maria G Kapetanaki; Oluwabukola T Gbotosho; Deva Sharma; Frances Weidert; Solomon F Ofori-Acquah; Gregory J Kato
Journal:  Free Radic Biol Med       Date:  2019-08-10       Impact factor: 7.376

6.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

Review 7.  Oxidative pathways in the sickle cell and beyond.

Authors:  Abdu I Alayash
Journal:  Blood Cells Mol Dis       Date:  2017-05-20       Impact factor: 3.039

Review 8.  How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.

Authors:  France Pirenne; Karina Yazdanbakhsh
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

Review 9.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

10.  Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factor.

Authors:  Xunde Wang; Laurel Mendelsohn; Heather Rogers; Susan Leitman; Nalini Raghavachari; Yanqin Yang; Yu Ying Yau; Michael Tallack; Andrew Perkins; James G Taylor; Constance Tom Noguchi; Gregory J Kato
Journal:  Blood       Date:  2014-06-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.